Guggenheim analyst Seamus Fernandez downgraded Sanofi (SNY) to Neutral from Buy.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi downgraded to Neutral from Overweight at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports